Aminosalicylic acid

When ATH:
J04AA01

Characteristic.

White or white with a slightly yellowish or slightly pinkish tinge crystalline powder, slightly soluble in water, quickly destroyed when heated, and when exposed to sunlight. The sodium salt is readily soluble in water, it is difficult - in alcohol, relatively stable at room temperature.

Pharmacological action.
Antiphthisic, bacteriostatic.

Application.

Drug-resistant tuberculosis (Various shapes and localization) in combination with other anti-backup means.

Contraindications.

Hypersensitivity, incl. other salicylates, severe kidney disease and liver (kidney and / or liver failure, Jade nontuberculous etiology, hepatitis, cirrhosis of the liver), amiloidoz, gastric ulcer and duodenal ulcer, enterocolitis (exacerbation), myxedema (uncompensated), decompensated heart failure (incl. against the background of heart disease), epilepsy.

In / in the introduction (additionally): tromboflebit, coagulation failure, expressed atherosclerosis.

Restrictions apply.

Moderately severe gastrointestinal pathology, deficiency of glucose-6-fosfatdegidrogenazы.

Pregnancy and breast-feeding.

Should not be used during pregnancy and breast-feeding (adequate and well-controlled studies in humans have not held). In one study, children, whose mothers took during pregnancy aminosalicylates simultaneously with other anti means, marked increase in the frequency of malformations of the ears and limbs, the occurrence of hypospadias. However, in other studies, teratogenic effects have been identified aminosalicylates.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Penetrates into breast milk, complications in humans has not been registered.

Side effects.

Cardio-vascular system and blood (hematopoiesis, hemostasis): violation of the synthesis of prothrombin, granulocytopenia or agranulocytosis, gemoliticheskaya anemia (in the definition, glucose-6-fosfatdegidrogenazы); seldom-B19, leukopenia (vploty to agranulocytosis), drug-induced hepatitis, IN₁₂-defitsitnaya megaloblastnaya anemia.

From the digestive tract: anorexia, nausea, vomiting, flatulence, diarrhea or constipation, gastric ulcer, gastrorrhagia, abdominal pain, increase in liver transaminases, giperʙiliruʙinemija, gepatomegaliya, hepatitis.

With the genitourinary system: kristallurija, proteinuria, hematuria.

Allergic reactions: hives, purpura, enanthema, drug fever, asthmatic effects, bronchospasm, arthralgia, eozinofilija.

Other: goiter with or without hypothyroidism, myxedema (long-term use in high doses), mononucleosis syndrome (fever, headache, skin rash, sore throat), diabetes, kaliopenia, metabolic acidosis; with a / in the introduction - sensation of heat, weakness, toxic-allergic reactions up to the development of shock.

Cooperation.

It interferes with the absorption of rifampin, Erythromycin, lincomycin and vitamin B₁₂ (the risk of anemia). Simultaneous treatment with aminobenzoate prevents bacteriostatic effect (competition mechanism of action). It may weaken the antibacterial effects of aminoglycosides. When combined with capreomycin may increase electrolyte abnormalities, decrease in the concentration of potassium and pH. Increases in blood concentrations of isoniazid, reducing its acetylation. It enhances the effect of coumarin derivatives and indandiona by decreasing hepatic synthesis of coagulation factors (require a dose adjustment of anticoagulants). Do not use together with pyrazinamide and ammonium chloride. Probenecid and sulfinpyrazone reduce tubular secretion, increasing the concentration aminosalicylic acid in the blood and the risk of toxic effects. The risk of developing hypothyroidism increases with concomitantly with ethionamide and prothionamide.

Dosing and Administration.

Inside, I /. Inside: after 0.5-1 hours after a meal, drinking milk, alkaline mineral water, 0,5-2% NaHCO. Adults - 3-4 g 3 once a day (in ambulatory practice - 9-12 g 1 reception), birth weight less than 50 kg - 6 g / day. In diseases of the gastrointestinal tract, Primary amyloidosis forms - 4-6 g / day. Children - an estimated 0,2 g / kg / day in 3-4 divided doses (no more 10 g / day). The course of treatment 1-2 years. B / drip: with speed 30, and through 15 min in the absence of local and systemic reactions - 40-60 drops per minute. At first infusion - no more 250 ml 3% solution, in the absence of side effects - on 500 ml, 5-6 Times a week or every other day, alternating with oral. The course of treatment 1-2 months or more.

Precautions.

Possible cross-sensitivity to the compounds, containing p-aminophenyl group (some sulfonamides and dyes). Patients, in which the acetylsalicylic acid tablets without coating causes gastrointestinal disorders, the drug should be administered in the form of pellets, tablets, or coated tablets, enterosoluble; possible temporary dose reduction or temporary cancellation of aminosalicylic acid, gradually increasing the dose to therapeutic. When the treatment is recommended to regularly monitoring of liver enzymes, Analysis of urine and blood. With the development of hematuria and proteinuria requires temporary cancellation PM. When using diabetic patients should be considered, granules which comprise 1 of the aminosalicylic acid 2 parts sugar (1 teaspoon seats 6 g pellet, corresponding 2 g aminosalicylic acid 4 g sugar). Should not be taken during aminosalicylic acid 6 hours before and after administration of rifampicin.

Cautions.

Solution, lost transparency or change color, unfit for consumption. May cause false positive result in the study of glycosuria, prevent the definition of urobilinogen (interaction with Ehrlich's reagent).

Cooperation